Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)
Brief Summary: Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection, if it persists, can lead over a long period of time to cancer of the cervix in women. In collaboration with MedImmune Inc., GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the adjuvant AS04. GSK Biologicals is also evaluating novel HPV vaccine formulations.This study will evaluate the immunogenicity and safety of a novel GSK Biologicals HPV vaccine in women 18-25 years of age at study start. Approximately 376 study subjects will receive the novel HPV vaccine or the control vaccine administered intramuscularly according to a 0-1-6 month schedule.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™ | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™; Assigned to Arm(s): Havrix Group
B: Arm Label: HPV-16/18 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV 16/18 L1 AS04 | Arm Label: HPV-TETRA A Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 1 | Arm Label: HPV-TETRA B Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 2 | Arm Label: HPV-TETRA C Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 3 | Arm Label: HPV-TETRA D Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 4 | Arm Label: HPV-TETRA E Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 5 | Arm Label: HPV-TETRA F Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 6 | Intervention Type: BIOLOGICAL; Name: HPV 16/18 L1 AS04; Assigned to Arm(s): HPV-16/18 Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 1; Assigned to Arm(s): HPV-TETRA A Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 2; Assigned to Arm(s): HPV-TETRA B Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 3; Assigned to Arm(s): HPV-TETRA C Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 4; Assigned to Arm(s): HPV-TETRA D Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 5; Assigned to Arm(s): HPV-TETRA E Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 6; Assigned to Arm(s): HPV-TETRA F Group
C: Arm Label: Cervarix™ & Engerix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™), Biological: Engerix™ | Arm Label: Engerix™ Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix™ | Intervention Type: BIOLOGICAL; Name: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™); Assigned to Arm(s): Cervarix™ & Engerix™ Group | Intervention Type: BIOLOGICAL; Name: Engerix™; Assigned to Arm(s): Cervarix™ & Engerix™ Group, Engerix™ Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: Gardasil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 1 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 2 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 3 | Intervention Type: BIOLOGICAL; Name: Comparator: Gardasil; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 1; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 2; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 3; Assigned to Arm(s): 4

Answer: B